65,437 trials
Small-cell Lung Cancer · SCLC · Small Cell Lung Cancer Limited Stage
Primary: Effect of Hippocampal-sparing Prophylactic Cranial Irradiation (PCI) on Possible Delayed Recall Toxicity as Assessed by the Hopkins Verbal Learning Test-Revised (HVLT-R)…
Ovarian Cancer · Fallopian Tube Neoplasms · Peritoneal Neoplasm
Primary: Part 2: Progression-Free Survival (PFS) — 18.9; 15.2 months
Respiratory Insufficiency · Dyspnea
Primary: Exercise Performance- Distance — 78.8; 88.6; 182.9; 165.2 meters
Low Milk Supply · Pre-diabetes · Insulin Resistance
Primary: Peak Change in Milk Output — 8; -58 milliliters
Depression
Primary: Double-Blind (DB) Induction Phase: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 — -15.2; -14.5; -15.1; -15.3 Units…
Atopic Dermatitis
Primary: Incidence of Treatment Emergent Adverse Events — 4; 2; 2; 1 Participants
Severe Acute Respiratory Syndrome · Ventilation Pneumonitis
Primary: Patients Who Improved Their Condition or Did Not Worsen it — 135; 12; 19 Participants
Feasibility
Primary: Retention of Subjects in Study Assessments — 14; 13 families
Health Behavior
Primary: HIV Knowledge Confidence — 42.9; 40.5 units on a scale — p=<.001
Bipolar Disorder
Primary: Number of Participants With Relapse of Major Depressive Episode Within 1 Year — 4; 5 Participants
Reperfusion Injury
Primary: Mortality — 0; 0 participants
Asthma
Primary: Change in Composite Asthma Severity Index (CASI) Score — 0.14; 2.4; -1.91 Change in score on a scale
Hypertension
Primary: 24-h, Wake and Sleep Period Systolic and Diastolic Blood Pressure — 137; 130; 133; 82 mmHg
Spinal Muscular Atrophy
Primary: Part 2: Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Midazolam Alone and in Combination With Risdiplam — 22.6; 25.1 h*ng/mL
LGMD2I
Primary: Incidence of Dose Limiting or Intolerability Treatment Related Adverse Events — 45; 21; 40; 0 events